Clinical trials: Esophagogastric Junction Disorder
Gastric Cancer, GastroEsophageal Cancer
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Cohort 1 [CLOSED] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment.
- Conditions
- Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
- Trial name
- SEQUEL (NCT04069273)
- Testing
- Pembrolizumab Monotherapy, Ramucirumab, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Harry H Yoon